Drug Trial Radar · NCT04882774
Telemonitoring to Treat Group 2 Pulmonary Hypertension
Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 2023
Primary completion
Apr 2025
Study completion Apr 2027
Sponsor
- Lead sponsor
- Mardi Gomberg -Maitland MD, MScAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ohio State University; Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- First posted
- May 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to decrease elevated pressure in the lungs of patients with pulmonary hypertension from left heart with elevated pulmonary vascular resistance by utilizing aggressive fluid management with ReDS Pro System and CardioMEMS device. Participants with persistently elevated pulmonary pressure at Week 16 will begin oral treprostinil in combination with the fluid management plan while those with improved pressures maintain their fluid management plan for an additional 16 weeks.
Conditions
- Pulmonary Hypertension Due to Left Heart Disease
Interventions
Treprostinil DiolamineDrug
Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with normal lung impedance as measured by the ReDS vest in Ohms at Week 16Time frame: 16 weeks
- Number of participants with normal total pulmonary resistance as measured by CardioMEMS in Woods Units at Week 16Time frame: 16 weeks
- Number of participants reaching normal lung impedance with oral treprostinil at Week 32Time frame: 16 weeks
- Number of participants reaching normal total pulmonary resistance with oral treprostinil at Week 32Time frame: 16 weeks
- Number of participants decreasing six-minute walk distance with oral treprostinil at Week 32Time frame: 16 weeks
- Number of participants maintaining normal lung impedance as measured by the ReDS vest at Week 32Time frame: 16 weeks
- Number of participants maintaining total pulmonary resistance as measured by CardioMEMS at Week 32Time frame: 16 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
George Washington University
Washington D.C., District of Columbia
Ohio State University
Columbus, Ohio
Allegheny Singer Research Institute
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.